Viridian Therapeutics, Inc. (VRDN) Tops Q4 EPS by 22c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q4 EPS of ($0.81), $0.22 better than the analyst estimate of ($1.03). Revenue for the quarter came in at $72 thousand versus the consensus estimate of $50.92 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Appeals court allows Trump administration to expand fast-track deportation process
• D-Wave Quantum (QBTS) call put ratio 5.3 calls to 1 put with a focus on July 26 and 30 calls as share price up 6.9%